Menu

Dengue Vaccine Program Halted Over Safety Issues

The drug may worsen future infections for people who haven't already been exposed to the virus.

Dec 5, 2017
Shawna Williams

ISTOCK, ESBEN_HThe Philippines has halted a dengue immunization program after the drug’s maker announced last week that its effectiveness is different in people who have not previously been exposed to the virus than in those who have, the Independent reports. The public health effort, begun last year, had vaccinated about 733,000 children at a cost of USD $70 million, according to STAT.

Two studies have suggested that for children who haven’t been exposed to dengue before vaccination, Dengvaxia, the drug made by France-based pharmaceutical company Sanofi, can actually increase the likelihood of hospitalization for the disease, STAT notes. “I do not believe . . . anybody should be going forward using this vaccine without testing the individual recipient to be sure they’re already seropositive. Because that’s the group that can benefit from this vaccine,” former U.S. Army scientist Scott Halstead told the outlet last year.

Harry Roque, a spokesperson for the Philippine president, said in a statement that the country’s health department is now closely monitoring people who received the vaccine. “We will leave no stone unturned in making those responsible for this shameless public health scam which puts hundreds of thousands of young lives at risk accountable,” Roque says, according to the Manila Bulletin.

The University of Minnesota’s Center for Infectious Disease Research and Policy reports that Dengvaxia took 20 years and $1 billion to develop, and was considered to be the first promising dengue vaccine. Halstead tells the publication that, “It's supposed to be a series of three shots, and now some [of the Filipino children vaccinated] only have had one, or two. . . . Sanofi has created a godawful mess, and we're going to have to slog along.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.